Transcript Paolo Pronzato - SciVal Experts is now part of Pure

Paolo Pronzato
Oncology, A.O.U. San Martino - IST, Istituto Nazionale Ricerca sul Cancro (GENOVA)
SciVal Experts URL: http://www.experts.scival.com/moh-it/expert.asp?n=Paolo+Pronzato&u_id=1569
170 Publications
2016
2016
2016
2015
2015
Matteo Lambertini; Paolo Bruzzi; Francesca Poggio; Simona Pastorino; Giovanni Gardin; Matteo
Clavarezza; Claudia Bighin; Paolo Pronzato; Lucia Del Mastro
Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and
taxane-based chemotherapy in breast cancer patients: a single-center experience within
the GIM2 randomized phase III trial
Supportive Care in Cancer. 2016;24(3):1285-1294. Lucia Del Mastro; Alessia Levaggi; Andrea Michelotti; Giovanna Cavazzini; Francesca Adami; Tiziana
Scotto; Margherita Piras; Saverio Danese; Ornella Garrone; Antonio Durando; Valeria Accortanzo;
Claudia Bighin; Loredana Miglietta; Simona Pastorino; Paolo Pronzato; Federico Castiglione; Elisabetta
Landucci; PierFranco Conte; Paolo Bruzzi
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in
node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial
Breast Cancer Research and Treatment. 2016;155(1):117-126. Lucia Del Mastro; Giovanni Rossi; Matteo Lambertini; Francesca Poggio; Paolo Pronzato
New insights on the role of luteinizing hormone releasing hormone agonists in
premenopausal early breast cancer patients
Cancer Treatment Reviews. 2016;42:18-23. Matteo Lambertini; Luca Boni; Andrea Michelotti; Teresa Gamucci; Tiziana Scotto; Stefania Gori; Monica
Giordano; Ornella Garrone; Alessia Levaggi; Francesca Poggio; Sara Giraudi; Claudia Bighin; Carlo
Vecchio; Mario Roberto Sertoli; Paolo Pronzato; Lucia Del Mastro
Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and
long-term ovarian function, pregnancies, and disease-free survival a randomized clinical
trial
JAMA - Journal of the American Medical Association. 2015;314(24):2632-2640. M. Lambertini; M. Ceppi; F. Poggio; F.A. Peccatori; H.A. Azim; D. Ugolini; P. Pronzato; S. Loibl; H.C.F.
Moore; A.H. Partridge; P. Bruzzi; L. Del Mastro
Ovarian suppression using luteinizing hormonereleasing hormone agonists during
chemotherapy to preserve ovarian function and fertility of breast cancer patients: A
meta-analysis of randomized studies
Annals of Oncology. 2015;26(12):2408-2419. 2015
Giovanni Orengo; Paolo Pronzato; Manlio Ferrarini
The OECI certification/designation program: The Genoa experience
Tumori. 2015;101:S19-S20. 2015
Matteo Lambertini; Arlindo R Ferreira; Lucia Del Mastro; Romano Danesi; Paolo Pronzato
Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients
with solid tumors
Expert Opinion on Biological Therapy. 2015. 2015
M. Aapro; V. Moebus; U. Nitz; J. O'Shaughnessy; P. Pronzato; M. Untch; D. Tomita; C. Bohac; B.
Leyland-Jones
Reply to letter to the editor 'Primum non nocere' by Templeton and Šeruga
Annals of Oncology. 2015;26(10):2198-2199. 2015
G. Mustacchi; L. Biganzoli; P. Pronzato; F. Montemurro; M. Dambrosio; M. Minelli; L. Molteni; L. Scaltriti
HER2-positive metastatic breast cancer: A changing scenario
Critical Reviews in Oncology/Hematology. 2015;95(1):78-87. 2015
2015
2014
2014
2014
2014
2014
2014
Matti Aapro; V. Moebus; U. Nitz; J. O'Shaughnessy; P. Pronzato; M. Untch; D. Tomita; C. Bohac; B.
Leyland-Jones
Safety and efficacy outcomes with erythropoiesisstimulating agents in patients with breast
cancer: A meta-analysis
Annals of Oncology. 2015;26(4):688-695. Sabino De Placido; Paolo Pronzato
Treatment options in HR+/HER2- advanced breast cancer patients pretreated with
nonsteroidal aromatase inhibitors: What does current evidence tell us?
Future Oncology. 2015;11(6):975-981. Alessia Levaggi; Andrea De Maria; Beatrice Dozin; Giuseppina Iacono; Claudia Bighin; Sara Giraudi;
Matteo Lambertini; Alessia D'Alonzo; Francesca Poggio; Paolo Pronzato; Lucia Del Mastro
Incidence of hepatitis in patients with evidence of past or current hepatitis B or C during
chemotherapy for early breast cancer
Anticancer Research. 2014;34(7):3715-3720. S. Barni; V. Lorusso; M. Giordano; G. Sogno; T. Gamucci; A. Santoro; R. Passalacqua; V. Iaffaioli; N.
Zilembo; M. Mencoboni; M. Roselli; G. Pappagallo; P. Pronzato
A prospective observational study to evaluate G-CSF usage in patients with solid tumors
receiving myelosuppressive chemotherapy in Italian clinical oncology practice
Medical Oncology. 2014;31(1). Matteo Lambertini; Lucia Del Mastro; Andrea Bellodi; Paolo Pronzato
The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating
factors (G-CSFs)
Critical Reviews in Oncology/Hematology. 2014;89(1):112-128. Stefania Vecchio; Francesco Spagnolo; Domenico F. Merlo; Alessio Signori; Mirko Acquati; Paolo
Pronzato; Paola Queirolo
The treatment of melanoma brain metastases before the advent of targeted therapies:
Associations between therapeutic choice, clinical symptoms and outcome with survival
Melanoma Research. 2014;24(1):61-67. Lucia Del Mastro; Marcello Ceppi; Francesca Poggio; Claudia Bighin; Fedro Peccatori; Isabelle
Demeestere; Alessia Levaggi; Sara Giraudi; Matteo Lambertini; Alessia D'Alonzo; Giuseppe Canavese;
Paolo Pronzato; Paolo Bruzzi
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced
premature ovarian failure in cancer women: Systematic review and meta-analysis of
randomized trials
Cancer Treatment Reviews. 2014;40(5):675-683. Erika Rijavec; Carlo Genova; Angela Alama; Giulia Barletta; Claudio Sini; Paolo Pronzato; Simona Coco;
Maria Giovanna Dal Bello; Graziana Savarino; Anna Truini; Francesco Boccardo; Francesco Grossi
Role of immunotherapy in the treatment of advanced non-small-cell lung cancer
2013
2013
2013
2013
2013
2013
2012
2012
2012
2012
Future Oncology. 2014;10(1):79-90. Francesco Grossi; Carlo Genova; Nidia Diaz Gaitan; Maria Giovanna Dal Bello; Erika Rijavec; Giulia
Barletta; Claudio Sini; Caterina Donato; Sabrina Beltramini; Paolo Pronzato; Gianfranco Porcile;
Francesco Boccardo; Stefan Walzer
Free drugs in clinical trials and their potential cost saving impact on the national health
service: A retrospective cost analysis in italy
Lung Cancer. 2013;81(2):236-240. Carlo Genova; Erika Rijavec; Anna Truini; Simona Coco; Claudio Sini; Giulia Barletta; Maria Giovanna Dal
Bello; Angela Alama; Grazia Savarino; Paolo Pronzato; Francesco Boccardo; Francesco Grossi
Pemetrexed for the treatment of non-small cell lung cancer
Expert Opinion on Pharmacotherapy. 2013;14(11):1545-1558. Claudia Bighin; Paolo Pronzato; Lucia Del Mastro
Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer
patients
Future Oncology. 2013;9(7):955-957. Roman Rouzier; Paolo Pronzato; Elisabeth Chéreau; Josh Carlson; Barnaby Hunt; William J. Valentine
Multigene assays and molecular markers in breast cancer: Systematic review of health
economic analyses
Breast Cancer Research and Treatment. 2013;139(3):621-637. Carlo Lazzaro; Roberto Bordonaro; Francesco Cognetti; Alessandra Fabi; Sabino De Placido; Grazia
Arpino; Paolo Marchetti; Andrea Botticelli; Paolo Pronzato; Elisa Martelli
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus
conventional paclitaxel for metastatic breast cancer patients: The COSTANza study
ClinicoEconomics and Outcomes Research. 2013;5(1):125-135. Grazia Arpino; Daniele Generali; Anna Sapino; Del Matro Lucia; Antonio Frassoldati; Michelino de
Laurentis; Pronzato Paolo; Giorgio Mustacchi; Marina Cazzaniga; Sabino De Placido; Pierfranco Conte;
Mariarosa Cappelletti; Vanessa Zanoni; Andrea Antonelli; Mario Martinotti; Fabio Puglisi; Alfredo Berruti;
Alberto Bottini; Luigi Dogliotti
Gene expression profiling in breast cancer: A clinical perspective
Breast. 2013;22(2):109-120. Lucia Del Mastro; Matteo Lambertini; Claudia Bighin; Alessia Levaggi; Alessia D'Alonzo; Sara Giraudi;
Paolo Pronzato
Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
Expert Review of Anticancer Therapy. 2012;12(11):1391-1405. Carlo Genova; Erika Rijavec; Giulia Barletta; Claudio Sini; Maria Giovanna Dal Bello; Mauro Truini;
Carmelina Murolo; Paolo Pronzato; Francesco Grossi
Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer
Expert Opinion on Biological Therapy. 2012;12(7):939-948. Matteo Lambertini; Lucia Del Mastro; Giovanni Gardin; Alessia Levaggi; Claudia Bighin; Sara Giraudi;
Paolo Pronzato
Stevens-Johnson syndrome after treatment with bendamustine
Leukemia Research. 2012;36(7):e153-e154. Francesco Grossi; Erika Rijavec; Maria Giovanna Dal Bello; Carlotta Defferrari; Annalisa Brianti; Giulia
Barletta; Carlo Genova; Carmelina Murolo; Maurizio Cosso; Gabriella Fontanini; Laura Boldrini; Mauro
Truini; Paolo Pronzato
2011
2011
2011
2011
2011
2011
The administration of gefitinib in patients with advanced non-small-cell lung cancer after
the failure of erlotinib
Cancer Chemotherapy and Pharmacology. 2012;69(6):1407-1412. Claudia Bello; Giovanna Dal Bello; Michele Cea; Aimable Nahimana; Dominique Aubry; Anna Garuti;
Giulia Motta; Eva Moran; Floriana Fruscione; Paolo Pronzato; Francesco Grossi; Franco Patrone; Alberto
Ballestrero; Marc Dupuis; Bernard Sordat; Kaspar Zimmermann; Jacqueline Loretan; Markus Wartmann;
Michel A. Duchosal; Alessio Nencioni; Pierre Vogel
Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols
Bioorganic and Medicinal Chemistry. 2011;19(24):7720-7727. Mario Airoldi; Dino Amadori; Sandro Barni; Saverio Cinieri; Sabino De Placido; Angelo Di Leo; Alessandra
Gennari; Stefano Iacobelli; Maria Teresa Ionta; Vito Lorusso; Marzia Lotrionte; Paolo Marchetti; Rodolfo
Mattioli; Giorgio Minotti; Paolo Pronzato; Giovanni Rosti; Carlo Alberto Tondini; Andrea Veronesi
Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast
cancer: A synthetic review
Tumori. 2011;97(6):690-692. Davide Bedognetti; Mario Roberto Sertoli; Paolo Pronzato; Lucia Del Mastro; Marco Venturini; Paola
Taveggia; Elisa Zanardi; Guido Siffredi; Simona Pastorino; Paola Queirolo; Giovanni Gardin; Ena Wang;
Clara Monzeglio; Francesco Boccardo; Paolo Bruzzi
Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: A
multicenter randomized phase III trial
Journal of the National Cancer Institute. 2011;103(20):1529-1539. Lucia Del Mastro; Luca Boni; Andrea Michelotti; Teresa Gamucci; Nina Olmeo; Stefania Gori; Monica
Giordano; Ornella Garrone; Paolo Pronzato; Claudia Bighin; Alessia Levaggi; Sara Giraudi; Nicola Cresti;
Emanuela Magnolfi; Tiziana Scotto; Carlo Vecchio; Marco Venturini
Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of
chemotherapy-induced early menopause in premenopausal women with breast cancer: A
randomized trial
JAMA - Journal of the American Medical Association. 2011;306(3):269-276. Lucia Del Mastro; Alessia Levaggi; Sara Giraudi; Paolo Pronzato
Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast
cancer patients: Current role and future perspectives
Cancer Treatment Reviews. 2011;37(3):208-211. Sandro Barni; Marco Maltoni; Guido Tuveri; Paolo Pronzato; Enrico Cortesi; Bruno Massidda; Giuseppe
Colucci; Carmelo Iacono; Vito Lorusso; Cesare Gridelli; Enrico Aitini; Lucia Simoni; Riccardo Torta
Attitude of Italian medical oncologists toward palliative care for patients with advanced
cancer: Results of the SIO project
Supportive Care in Cancer. 2011;19(3):381-389. 2011
Lucia Del Mastro; Sara Giraudi; Alessia Levaggi; Paolo Pronzato
Medical approaches to preservation of fertility in female cancer patients
Expert Opinion on Pharmacotherapy. 2011;12(3):387-396. 2011
M. Lambertini; P. Pronzato; S. Giraudi; A. Levaggi; C. Bighin; L. del Mastro
Letrozole withdrawal response in locally advanced breast cancer
Annals of Oncology. 2011;22(8):1927-1928. 2010
Claudia Bighin; Lucia Del Mastro; Giuseppe Canavese; Franca Carli; Paola Taveggia; Alessia Levaggi;
Sara Giraudi; Paolo Pronzato
Use in current clinical practice of 70-gene signature in early breast cancer
International Journal of Cancer. 2010;127(11):2736-2737. 2010
2010
2010
2010
2010
2010
2009
2009
2009
Claudia Bighin; Gianluigi Lunardi; Lucia del Mastro; Paola Marroni; Paola Taveggia; Alessia Levaggi; Sara
Giraudi; Paolo Pronzato
Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated
with aromatase inhibitors
Oncologist. 2010;15(12):1270-1272. Françoise Borcard; Matthias Baud; Claudia Bello; Giovanna Dal Bello; Francesco Grossi; Paolo Pronzato;
Michele Cea; Alessio Nencioni; Pierre Vogel
Synthesis of new oxathiazinane dioxides and their in vitro cancer cell growth inhibitory
activity
Bioorganic and Medicinal Chemistry Letters. 2010;20(17):5353-5356. Claudia Bello; Michele Cea; Giovanna Dal Bello; Anna Garuti; Ilaria Rocco; Gabriella Cirmena; Eva
Moran; Aimable Nahimana; Michel A. Duchosal; Floriana Fruscione; Paolo Pronzato; Francesco Grossi;
Franco Patrone; Alberto Ballestrero; Marc Dupuis; Bernard Sordat; Alessio Nencioni; Pierre Vogel
Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as α-mannosidase inhibitors
and with antitumor activities against hematological and solid malignancies
Bioorganic and Medicinal Chemistry. 2010;18(9):3320-3334. L. del Mastro; C. Bighin; G. Bini; S. Giraudi; P. Taveggia; A. Levaggi; G. Canavese; G. Rescinito; P.
Pronzato
Trastuzumab before breast surgery: Is concurrent administration with
anthracycline-containing chemotherapy necessary?
Annals of Oncology. 2010;21(6):1376-1377. Paolo Spallarossa; Paola Altieri; Paolo Pronzato; Concetta Aloi; Giorgio Ghigliotti; Antonio Barsotti;
Claudio Brunelli
Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes
sensitized by low prosenescent doses of epirubicin: The protective role of dexrazoxane
Journal of Pharmacology and Experimental Therapeutics. 2010;332(1):87-96. Paolo Pronzato; Enrico Cortesi; Carin C. van der Rijt; Alain Bols; José A. Moreno-Nogueira; Carlos Freire
de Oliveira; Peter Barrett-Lee; Peter J. Ostler; Ricardo Rosso
Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients
with breast cancer receiving myelotoxic chemotherapy: Results of a european, multicenter,
randomized, controlled trial
Oncologist. 2010;15(9):935-943. B. Banelli; I. Casciano; A. di Vinci; B. Gatteschi; A. Levaggi; F. Carli; C. Bighin; S. Salvi; G. Allemanni; P.
Ghiorzo; P. Pronzato; M. Venturini; M. Romani; L. del Mastro
Pathological and molecular characteristics distinguishing contralateral metastatic from new
primary breast cancer
Annals of Oncology. 2009;21(6):1237-1242. Francesco Grossi; Marianna Aita; Carlotta Defferrari; Francesco Rosetti; Annalisa Brianti; Gianpiero
Fasola; Orazio Vinante; Paolo Pronzato; Giovanni Pappagallo
Impact of third-generation drugs on the activity of first-line chemotherapy in advanced
non-small cell lung cancer: A meta-analytical approach
Oncologist. 2009;14(5):497-510. Olaf Ortmann; Tanja Cufer; J. Michael Dixon; Nicolai Maass; Paolo Marchetti; Olivia Pagani; Paolo
Pronzato; Vladimir Semiglazov; Jean-Philippe Spano; Eduard Vrdoljak; Hans Wildiers
Adjuvant endocrine therapy for perimenopausal women with early breast cancer
Breast. 2009;18(1):2-7. 2008
2008
2008
2008
2008
2008
2008
2008
2007
Marianna Aita; Gianpiero Fasola; Carlotta Defferrari; Annalisa Brianti; Maria Giovanna Dal Bello;
Alessandro Follador; Graziella Sinaccio; Paolo Pronzato; Francesco Grossi
Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell
lung cancer
Critical Reviews in Oncology/Hematology. 2008;68(3):183-196. Valentina Guarneri; Antonio Frassoldati; Paolo Bruzzi; Roberto D'Amico; Maurizio Belfiglio; Annamaria
Molino; Oscar Bertetto; Stefano Cascinu; Francesco Cognetti; Angelo Di Leo; Paolo Pronzato; Lucio
Crinó; Biagio Agostara; Pierfranco Conte
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens
plus three versus twelve months of trastuzumab in patients with HER2- positive breast
cancer (Short-HER Trial; NCT00629278)
Clinical Breast Cancer. 2008;8(5):453-456. Silvio Roncella; Paola Ferro; Bartolomeo Bacigalupo; Paolo Dessanti; Paolo Pronzato; Maria Cristiana
Zranceschini; Luca Pratticò; Anna Maria Carletti; Pier Aldo Canessa; Vincenzo Fontana; Franco Fais;
Maria Pia Pistillo; Franco Fedeli
Assessment of RT-PCR detection of human mammaglobin for the diagnosis of breast cancer
derived pleural effusions
Diagnostic Molecular Pathology. 2008;17(1):28-33. Lucia Del Mastro; B. Dozin; E. Aitini; T. Catzeddu; E. Baldini; A. Contu; A. Durando; S. Danese; G.
Cavazzini; G. Canavese; P. Bruzzi; P. Pronzato; M. Venturini; G. Porcile; F. Testore; V. Mascia; E. De
Fraia; M. Botta; M. Merlano; M. Mencoboni; E. Campora; F. Brema; A. Lavarello; M. Campogrande; C.
Caroti; A. Falcone; S. Banducci; E. Villa; D. Aldighetti; M. Danova; U. Folco; E. Cortesi; G. D'Auria; N.
Olmeo; A. Pazzola; G. Mustacchi; C. Dellach
Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: Findings
from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo
(GONO-MIG) Group
Annals of Oncology. 2008;19(2):299-307. Alessandra Gennari; Paolo Pronzato
New understanding of the role of anthracyclines in early-stage breast cancer: patient
selection considerations
Clinical Breast Cancer. 2008;8(SUPPL. 4):S179-S183. M.E. Cazzaniga; P. Pronzato; G. Mustacchi; A. De Matteis; F. Di Costanzo; E. Rulli; I. Floriani
The anthracyclines and the clinical practice: Do all breast cancer patients benefit? Results
from the NORA study
Annals of Oncology. 2008;19(10):1811-1812. Alessandra Gennari; Maria Pia Sormani; Paolo Pronzato; Matteo Puntoni; Mariantonietta Colozza; Ulrich
Pfeffer; Paolo Bruzzi
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled
analysis of randomized trials
Journal of the National Cancer Institute. 2008;100(1):14-20. Paolo Pronzato
New therapeutic options for chemotherapy-resistant metastatic breast cancer: The
epothilones
Drugs. 2008;68(2):139-146. M.E. Cazzaniga; G. Mustacchi; P. Pronzato; A. De matteis; F. Di Costanzo; I. Floriani
Adjuvant treatment of early breast cancer: Do the St Gallen recommendations influence
clinical practice? Results from the NORA study
Annals of Oncology. 2007;18(12):1976-1980. 2007
Matteo Clavarezza; Lucia Del Mastro; Paolo Pronzato; Paolo Bruzzi; Marco Venturini
Re: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte
colony-stimulating factors during breast cancer adjuvant chemotherapy [2]
Journal of the National Cancer Institute. 2007;99(13):1050-1051. 2007
G. Mustacchi; M.E. Cazzaniga; P. Pronzato; A. De Matteis; F. Di Costanzo; I. Floriani
Breast cancer in elderly women: A different reality? Results from the NORA study
Annals of Oncology. 2007;18(6):991-996. 2006
Fritz Jänicke; Paolo Pronzato
What is the optimal strategy for postoperative treatment with aromatase inhibitors in the
adjuvant setting?
Best Practice and Research: Clinical Endocrinology and Metabolism. 2006;20(SUPPL. 1):S31-S45. 2006
M.E. Cazzaniga; G. Mustacchi; P. Pronzato; A. De Matteis; F. Di Costanzo; I. Floriani
Adjuvant systemic treatment of early breast cancer: The NORA study
Annals of Oncology. 2006;17(9):1386-1392. 2006
Maurizio Marangolo; Carmelo Bengala; Pier Franco Conte; Marco Danova; Paolo Pronzato; Giovanni
Rosti; Paola Sagrada
Dose and outcome: The hurdle of neutropenia (Review)
Oncology Reports. 2006;16(2):233-248. 2006
P. Pronzato; M. Rondini
First line chemotherapy of metastatic breast cancer
Annals of Oncology. 2006;17(SUPPL. 5):v165-v168. 2006
Paolo Pronzato; Jacek Jassem; Jose Mayordomo
Epoetin beta therapy in patients with solid tumours
Critical Reviews in Oncology/Hematology. 2006;58(1):46-52. 2006
Silvio Roncella; P. Ferro; B. Bacigalupo; P. Dessanti; A. Giannico; N. Gorji; M. Moroni; S. Tozzini; F.
Pensa; D. Gianquinto; F. Fais; P. Pronzato; F. Fedeli
Relationship between human mammaglobin mRNA expression in breast cancer tissue and
clinico-pathologic features of the tumors
Journal of Experimental and Clinical Cancer Research. 2006;25(1):65-72. 2006
Paolo Pronzato
Cancer-related anaemia management in the 21st century
Cancer Treatment Reviews. 2006;32(SUPPL. 2):S1-S3. 2005
2005
Marco Venturini; Lucia Del Mastro; Enrico Aitini; Editta Baldini; Cinzia Caroti; Antonio Contu; Franco
Testore; Fulvio Brema; Paolo Pronzato; Giovanna Cavazzini; Mario Roberto Sertoli; Giuseppe Canavese;
Riccardo Rosso; Paolo Bruzzi
Dose-dense adjuvant chemotherapy in early breast cancer patients: Results from a
randomized trial
Journal of the National Cancer Institute. 2005;97(23):1724-1733. Silvio Roncella; P. Ferro; B. Bacigalupo; P. Pronzato; A. Tognoni; E. Falco; D. Gianquinto; V. Ansaldo; P.
Dessanti; F. Fais; J. Rosai; F. Fedeli
Human mammaglobin mRNA is a reliable molecular marker for detecting occult breast
cancer cells in peripheral blood
Journal of Experimental and Clinical Cancer Research. 2005;24(2):265-271. 2005
2005
2005
2004
2004
2003
P. Pronzato; M. Rondini
Hormonotherapy of advanced prostate cancer
Annals of Oncology. 2005;16(SUPPL. 4):iv80-iv84. Luigi Portalone; Antonio Antilli; Francesco Nunziati; Carlo Crispino; Filippo DeMarinis; Luigi Friggeri;
Alessandra Lombardi; Vito LoRusso; Paolo Pronzato; Domenico Sambiasi; Mauro Signora
Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma
Tumori. 2005;91(1):15-18. Enrico Cortesi; Pere Gascón; David Henry; Timothy Littlewood; Robert Milroy; Paolo Pronzato; Uwe
Reinhardt; Daniel Shasha; Nicholas Thatcher; Peter Wilkinson
Standard of care for cancer-related anemia: Improving hemoglobin levels and quality of life
Oncology. 2005;68(SUPPL. 1):22-32. Silvana Chiara; Alessandra Tognoni; Ilaria Pastrone; Laura Tomasello; Fulvio Brema; Gianna Di
Costanzo; Ugo Folco; Paolo Pronzato
Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer
Gynecologic Oncology. 2004;93(2):474-478. M. Cazzaniga; P. Pronzato; S.L. Leto Di Priolo; A. De Matteis; F. Di Costanzo; R. Passalacqua; R. Rosso;
V. Torri
Patterns of relapse and modalities of treatment of breast cancer: The 'IRIS' project, a
multicenter observational study
Oncology. 2004;66(4):260-268. F. Di Costanzo; A. Sobrero; S. Gasperoni; L. Dogliotti; L. Frassineti; A. Falcone; R. Lionetto; P. Bruzzi; G.
Luppi; L. Gallo; P. Conte; A. Comandone; D. Turci; M. Marzola; U. Folco; E. Pfanner; M. Mestriner; C.
Boni; C. Galli; M. Tonato; R. Rosso; A. Lavarello; F. Brema; G. Pastorino; G. Bottero; V. Fusco; G. Orsi;
D. Cocchis; A. Guglielmi; P. Pronzato; G. Barsanti; M. Battistoni; P. Grezzi; M. Rinaldini; R. Taviani; M.
Aglietta; C. Volta; R. Algeri; P. De Gennaro; I. Spinelli; M. Filidei; G. Arcabasso; A. Carli; R. Antonacci; C.
Bumma; R. Berardo; A. Boglione; A. Di Napoli; M. Merlano; G. Grecchi; G. Porcile; M. Destefanis; O.
Alabiso; R. Buosi; M. Botta; B. Castagneto; V.M. Zampaglione; P. Sozzi; V. Sidoti; S. Di Prima; D.
Amadori; O. Nanni; P. Rosetti; M. Marangolo; F. Zumaglini; D. Tassinari; E. Pasquini; F. Artioli; M.
Cesari; A. Gambi; L. Amaducci; P. Alessandrini; G. Catalano
Adjuvant chemotherapy in the treatment of colon cancer: Randomized multicenter trial of
the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC)
Annals of Oncology. 2003;14(9):1365-1372. 2003
Annunziata Manna; Stefano Cordani; Pieraldo Canessa; Paolo Pronzato
CMV infection and pneumonia in hematological malignancies
Journal of Infection and Chemotherapy. 2003;9(3):265-267. 2002
A. Tognoni; F. Pensa; F. Vaira; A. Vigani; P. Canessa; G. Sinaccio; P. Pronzato
A dose finding study of carboplatin and gemcitabine in advanced non-small cell lung cancer
Journal of Chemotherapy. 2002;14(3):296-300. 2002
2001
G. Bertelli; M. Venturini; L. Del Mastro; M. Bergaglio; P. Sismondi; N. Biglia; S. Venturini; G. Porcile; P.
Pronzato; M. Costantini; R. Rosso
Intramuscular depot medroxyprogesterone versus oral megestrol for the control of
postmenopausal hot flashes in breast cancer patients: A randomised study
Annals of Oncology. 2002;13(6):883-888. Gianni Bernardo; Massimo Aglietta; Dino Amadori; Patrizia Beccaglia; Gianfranco Belli; Raffaele Bianco;
Luca Cionini; Francesco Cognetti; Giuseppe Colucci; Giuseppe Comelia; Francesco Di Costanzo; Paolo
2001
2001
2001
Marchetti; Paolo Pronzato
The prevalence of anemia in cancer patients undergoing chemotherapy: A nation-wide
survey in Italy
Recenti Progressi in Medicina. 2001;92(10):580-588. L. Del Mastro; M. Venturini; R. Lionetto; F. Carnino; D. Guarneri; L. Gallo; A. Contu; P. Pronzato; L.
Vesentini; M. Bergaglio; S. Comis; R. Rosso
Accelerated-intensified Cyclophosphamide, Epirubicin, and Fluorouracil (CEF) compared
with standard CEF in metastatic breast cancer patients: Results of a multicenter,
randomized phase III study of the Italian gruppo oncologico nord-quest-mammella inter
gruppo group
Journal of Clinical Oncology. 2001;19(8):2213-2221. A. Tognoni; F. Pensa; F. Vaira; A. Vigani; L. Bancalari; L. Fiasella; R. Maggiani; P. Canessa; P. Pronzato
A three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small-cell
lung cancer
Journal of Chemotherapy. 2001;13(2):202-205. Paolo Pronzato; Paola Queirolo; Stefania Vecchio; Rita Lionetto; Lucia Del Mastro; Marco Venturini;
Giovanni Gardin; Angela Alama; Mario R. Sertoli
Thymidine labeling index analysis in early breast cancer patients randomized to receive
perioperative chemotherapy
Oncology. 2001;60(1):88-93. 2001
Paolo Pronzato; A. Vigani; A. Tognoni; F. Vaira; P. Canessa
Anthacyclines in non-small cell lung cancer
Lung Cancer. 2001;34(SUPPL. 4):57-59. 2000
2000
Antonella Venturino; Danila Comandini; Carlotta Simoni; Laura Merlini; Cinzia Naso; Raffaella Palumbo;
Vittorio Fusco; Gianfranco Porcile; Paolo Pronzato; Riccardo Rosso; Lazzaro Repetto
Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated?
A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus
combination of mitoxantrone, 5-fluorouracil plus leucovorin
Breast Cancer Research and Treatment. 2000;60(3):195-200. A. Vigani; F. Pensa; F. Vaira; L. Bancalari; S. Cordani; R. Maggiani; P. Canessa; P. Pronzato
Sequential high dose-density chemotherapy with two active regimens for advanced small
cell lung cancer
Anticancer Research. 2000;20(5 C):4015-4018. 2000
A. Tognoni; P. Pronzato; L. Cadenotti; E. Ghio; N. Manna; F. Pensa; L. Marino
Sequential high dose-density chemotherapy in advanced ovarian cancer
Anticancer Research. 2000;20(5 C):3957-3961. 1999
1998
Alessandra Tognoni; L. Cadenotti; F. Pensa; F. Vaira; A. Vigani; L. Bancalari; S. Cordani; R. Maggiani;
P.A. Canessa; P. Pronzato
A phase II study of a three-drug combination (cisplatin, ifosfamide and vinorelbine) plus
granulocyte-colony stimulating factor in advanced non small cell lung cancer
Journal of Chemotherapy. 1999;11(4):306-309. P. Pronzato; R. Lionetto; F. Botto; F. Pensa; A. Tognoni
High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by
shortened intervals and granulocyte colony-stimulating factor in non Hodgkin's lymphoma:
A phase II study
British Journal of Cancer. 1998;78(6):777-780. 1998
1998
P. Pronzato; A. Tognoni; F. Pensa; F. Vaira; A. Vigani
A dose finding study for the combination of epidoxorubicin and vinorelbine, delivered every
two weeks with G-CSF support, in advanced breast cancer
Journal of Chemotherapy. 1998;10(4):326-330. P. Pronzato; F. Botto; E. Ghio; F. Pensa; A. Tognoni; F. Vaira; A. Vigani; E. Neri
A phase II trial of carboplatin, methotrexate and fluorouracil in fluorouracii-pretreated
colorectal cancer
Journal of Chemotherapy. 1998;10(3):254-257. 1998
Paolo Pronzato; Pierluigi Losardo; Floriana Pensa; Alessandra Tognoni
High-dose-intensity combination chemotherapy for advanced sarcomas: A pilot study
Cancer Chemotherapy and Pharmacology. 1998;41(6):513-516. 1997
Paolo Pronzato; Antonella Vigani; Floriana Pensa; Maurizio Vanoli; Francesco Tani; Franco Vaira
Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder
cancer
American Journal of Clinical Oncology: Cancer Clinical Trials. 1997;20(5):519-521. 1997
Paolo Pronzato; Floriana Pensa; Franco Vaira; Antonella Vigani
Low dose GM-CSF and dose intensity of antitumor chemotherapy
Tumori. 1997;83(5 SUPPL.):S8-S12. 1997
1997
Paolo Pronzato; Antonella Vigani; Floriana Pensa; Floriana Botto; Ermanno Ghio; Elisabetta Neri;
Alessandra Tognoni; Franco Vaira
A new schedule for Etoposide, Epidoxorubicin and Cisplatin with Granulocyte Colony
Stimulating Factor for advanced gastric cancer: A feasibility study
Anticancer Research. 1997;17(5 B):3873-3876. Editta Baldini; Giovanni Gardin; Piergiorgio Giannessi; Fulvio Brema; Alessandra Camorriano; Flavio
Carnino; Cinzia Naso; Giuliana Pastorino; Paolo Pronzato; Riccardo Rosso; Alessandra Rubagotti; Giorgio
Torretta; Pier Franco Conte
A randomized trial of chemotherapy with or without estrogenic recruitment in locally
advanced breast cancer
Tumori. 1997;83(5):829-833. 1997
Paolo Pronzato; Floriana Pensa; Franco Vaira; Antonella Vigani
GM-CSF a basse dosi e intensità della chemioterapia antitumorale
Tumori. 1997;83(5 SUPPL. 1):S8-S12. 1997
1997
Maria Cristina Pennucci; Andrea Ardizzoni; Paolo Pronzato; Marina Fioretti; Claudio Lanfranco; Anna
Verna; Guglielmina Giorgi; Antonella Vigani; Carlo Frola; Riccardo Rosso
Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural
mesothelioma: A Phase II FONICAP trial
Cancer. 1997;79(10):1897-1902. Paolo Pronzato; Gianfilippo Bertelli; Francesco Bruna; Franco Tani; Franco Vaira; Maurizio Vanoli;
Antonella Vigani
Intensified M-VEC chemotherapy with G-CSF support as outpatient treatment for advanced
bladder cancer
Anticancer Research. 1997;17(3 C):2325-2327. 1997
P. Pronzato; P. Queirolo; M. Landucci; F. Vaira; A. Vigani; M. Gipponi; F. Cafiero
1996
1996
1996
1996
1996
1996
Phase II study of vinorelbine and ifosfamide in anthtracycline resistent metastatic breast
cancer
Breast Cancer Research and Treatment. 1997;42(2):183-186. P.F. Conte; E. Baldini; G. Gardin; P. Pronzato; D. Amadori; F. Carnino; C. Monzeglio; P. Gentilini; P.
Gallotti; R. De Micheli; M. Venturini; A. Rubagotti; R. Rosso
Chemotherapy with or without estrogenic recruitment in metastatic breast cancer. A
randomized trial of the Gruppo Oncologico Nord Ovest (GONO)
Annals of Oncology. 1996;7(5):487-490. M. Venturini; A. Michelotti; L. Del Mastro; L. Gallo; F. Carnino; O. Garrone; C. Tibaldi; N. Molea; R.C.
Bellina; P. Pronzato; P. Cyrus; J. Vinke; F. Testore; M. Guelfi; R. Lionetto; P. Bruzzi; P.F. Conte; R. Rosso
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane
versus no cardioprotection in women receiving epirubicin chemotherapy for advanced
breast cancer
Journal of Clinical Oncology. 1996;14(12):3112-3120. Lazzaro Repetto; Pier Giorgio Giannessi; Elisabetta Campora; Paolo Pronzato; Antonella Vigani; Cinzia
Naso; Italo Spinelli; Pier Franco Conte; Riccardo Rosso
Tamoxifen and interferon-beta for the treatment of metastatic breast cancer
Breast Cancer Research and Treatment. 1996;39(2):235-238. Paolo Pronzato
Interleukin-2 and interferon α 2 combination: Ineffectiveness of a single six-week course in
patients with metastatic renal cancer pretreated with interferon alone
Oncology Reports. 1996;3(6):1137-1139. P. Pronzato; G. Bertelli; A. Vigani; F. Vaira
A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and
cyclophosphamide (PEC) in advanced ovarian cancer
British Journal of Cancer. 1996;73(11):1425-1427. G. Gardin; C. Barone; O. Nascimben; G. Ianniello; F. Sturba; A. Contu; P. Pronzato; R. Rosso
Lonidamine plus Epirubicin and Cyclophosphamide in Advanced Breast Cancer. A Phase II
Study
European Journal of Cancer. 1996;32(1):176-177. 1996
Paolo Pronzato
Tropisetron-dexamethasone combination for carboplatin-induced emesis
Oncology Reports. 1996;3(6):1179-1181. 1996
Paolo Pronzato; Ermanno Ghio; Pier Luigi Losardo; Marco Landucci; Franco Vaira; Antonella Vigani
Carboplatin and vinorelbine in advanced non-small-cell lung cancer
Cancer Chemotherapy and Pharmacology. 1996;37(6):610-612. 1995
1995
M.R. Sertoli; P. Bruzzi; P. Pronzato; P. Queirolo; D. Amoroso; L. Del Mastro; M. Venturini; A. Vigani; G.
Bertelli; E. Campora; F. Boccardo; C. Monzeglio; E. Paganini; G. Pastorino; G. Canavese; A. Catturich; F.
Cafiero; C. Vecchio; P. Miccoli; A. Rubagotti; R. Rosso
Randomized cooperative study of perioperative chemotherapy in breast cancer
Journal of Clinical Oncology. 1995;13(11):2712-2721. P. Pronzato; M. Landucci; F. Vaira; A. Vigani; G. Bertelli
Carboplatin, methotrexate, and vinblastine in outpatients with advanced transitional cell
carcinoma of the bladder
1995
1995
1995
American Journal of Clinical Oncology: Cancer Clinical Trials. 1995;18(3):223-225. P. Pronzato; F. Bruna; E. Neri; D. Roveri; A. Trabucchi; M. Vanoli; A. Vigani; F. Vaira; P. Losardo; G.
Bertelli
Radiotherapy plus carboplatin and teniposide in patients with brain metastases from non
small cell lung cancer
Anticancer Research. 1995;15(2):517-519. G. Gardin; R. Rosso; E. Campora; L. Repetto; C. Naso; G. Canavese; A. Catturich; R. Corvò; M. Guenzi;
P. Pronzato; E. Baldini; P.F. Conte
Locally advanced non-metastatic breast cancer: Analysis of prognostic factors in 125
patients homogeneously treated with a combined modality approach
European Journal of Cancer. 1995;31(9):1428-1433. P. Pronzato; F. Vaira; A. Vigani; P. Losardo; G. Bertelli
Biochemical modulation of 5-fluorouracil with methotrexate in advanced colorectal cancer
patients pretreated with adjuvant 5-fluorouracil and leucovorin
Anticancer Research. 1995;15(6 B):2679-2682. 1995
P. Pronzato; P.L. Losardo; F. Vaira; A. Vigani; M. Landucci; E. Ghio
Granisetron-dexamethasone combination for multiple day cisplatin
Anticancer Research. 1995;15(5 B):2261-2263. 1994
G. Bertelli; D. Dini; G.B. Forno; A. Gozza; S. Silvestro; M. Venturini; R. Rosso; P. Pronzato
Hyaluronidase as an antidote to extravasation of Vinca alkaloids: Clinical results
Journal of Cancer Research and Clinical Oncology. 1994;120(8):505-506. 1994
Paolo Pronzato; Gianfilippo Bertelli; Pierluigi Losardo; Marco Landucci
What do advanced cancer patients know of their disease? - A report from Italy
Supportive Care in Cancer. 1994;2(4):242-244. 1994
1994
1994
1994
S. Toma; R. Palumbo; M. Vincenti; E. Aitini; G. Paganini; P. Pronzato; A. Grimaldi; R. Rosso
Efficacy of recombinant alpha-interferon 2a and 13-cis-retinoic acid in the treatment of
squamous cell carcinoma
Annals of Oncology. 1994;5(5):463-465. G. Gardin; A. Alama; R. Rosso; E. Campora; L. Repetto; P. Pronzato; L. Merlini; C. Naso; A. Camoriano;
R. Meazza; F. Barbieri; E. Baldini; P.G. Giannessi; P.F. Conte
Relationship of variations in tumor cell kinetics induced by primary chemotherapy to tumor
regression and prognosis in locally advanced breast cancer
Breast Cancer Research and Treatment. 1994;32(3):311-318. P. Pronzato; M. Landucci; F. Vaira; A. Vigani; G. Bertelli
Failure of vinorelbine to produce responses in pretreated non-small cell lung cancer
patients
Anticancer Research. 1994;14(3 B):1413-1415. P. Pronzato; G. Bertelli; F. Vaira; A. Vigani; P. Losardo
Mitoxantrone and 5-fluorouracil modulated by the pure (6S) stereoisomer of leucovorin as
second-line chemotherapy for advanced breast cancer
European Journal of Cancer. 1994;30(10):1593-1594. 1994
Paolo Pronzato; Marco Landuccia; Franco Vairaa; Antonella Vigania; Gianfdippo Bertelli
1993
Carboplatin and etoposide as outpatient treatment of advanced non-small-cell lung cancer
Chemotherapy. 1994;40(2):144-148. P. Pronzato; A. Rubagotti; D. Amoroso; G. Bertelli; P. Queirolo; M.R. Sertoli; M. Rosso; P. Gallotti; C.
Monzeglio; R. Rosso
Second-line hormonotherapy for breast cancer: Uselessness of first-line continuation
American Journal of Clinical Oncology: Cancer Clinical Trials. 1993;16(6):522-525. 1993
P. Pronzato; G. Bertelli; G. Gardin; A. Rubagotti; P.F. Conte; R. Rosso
Analysis of time to response to chemotherapy in 316 metastatic breast cancer patients
Oncology. 1993;50(6):460-465. 1993
P. Pronzato; L. Miglietta; A. Rubagotti; G. Bertelli; P. Queirolo; M. Guenzi; M.R. Sertoli; V. Vitale; R.
Rosso
Impact of irradiation of residual breast on adjuvant chemotherapy dose intensity
American Journal of Clinical Oncology: Cancer Clinical Trials. 1993;16(1):58-60. 1993
C. Naso; C. Simoni; L. Merlini; M. Rosso; P. Pronzato; L. Repetto; G. Gardin; R. Rosso
Lymphoblastoid interferon in advanced breast cancer: A phase II study
Journal of Chemotherapy. 1993;5(4):258-261. 1993
1993
1993
1992
1992
1991
P. Pronzato; G. Bertelli; M. Rosso
A randomized trial on tamoxifen continuation during second-line hormone therapy in breast
cancer
Annals of the New York Academy of Sciences. 1993;698:357-361. E. Baldini; G. Gardin; C. Naso; P. Pronzato; R. Rosso; A. Rubagotti; C. Monzeglio; F. Brema; G.
Pastorino; D. Amadori; P. Gentilini; P. Gallotti; G. Pavanato; F. Testore; C. Lanfranco; P.G. Giannessi;
P.F. Conte
Stimulation of human breast cancer in vivo. Experimental findings and clinical results
Annals of the New York Academy of Sciences. 1993;698:418-422. R. Rosso; G. Gardin; P. Pronzato; A. Camoriano; L. Merlini; C. Naso; M. Rosso; C. Barone; O.
Nascimben; G. Ianniello; F. Sturba; A. Contu; E. Baldini; P.G. Giannessi; P.F. Conte
The role of lonidamine in the treatment of breast cancer patients
Annals of the New York Academy of Sciences. 1993;698:349-356. E. Campora; P. Pronzato; D. Amoroso; G.F. Bertelli; M. Venturini; E. Baldini; I. Brunetti; M.R. Sertoli; P.
Conte; R. Rosso
Prognostic factors in node positive primary breast cancer patients treated with adjuvant
CMF
Anticancer Research. 1992;12(5):1555-1558. L. Repetto; L. Miglietta; G. Gardin; C. Naso; S. Giudici; L. Merlini; P. Queirolo; E. Campora; P. Pronzato;
R. Rosso
Mitoxantrone and mitomycin C as second-line treatment for advanced breast cancer
Annals of Oncology. 1992;3(2):165-166. P. Queirolo; L. Repetto; G. Gardin; L. Miglietta; T. Guido; P. Pronzato; R. Rosso
Intensive chemotherapy with cisplatin, mitoxantrone, methotrexate and vincristine in
metastatic breast cancer
Journal of Chemotherapy. 1991;3(3):194-197. 1991
1991
1991
Riccardo Rosso; Domenico Amoroso; Giovanni Gardin; Loredana Miglietta; Tiziana Guido; Maurizio Pace;
Lazzaro Repetto; Paolo Pronzato
Lonidamine in metastatic breast cancer
Seminars in Oncology. 1991;18(2 SUPPL. 4):62-65. A.R. Bianco; R. Rosso; F. Calabresi; M. Fiorentino; M. Lopez; P.G. Sismondi; R. Lenti; V. Fosser; S. De
Placido; F. Perrone; P. Pronzato; P. Carlini; A. Fornasiero; E. Veltri; P. Zola; M. Farinacci; M. Gulisano; R.
Artioli
LH-RH analogue Zoladex in the treatment of pre- and perimenopausal women with
metastatic breast cancer (results of the Italian Cooperative Study)
European Journal of Gynaecological Oncology. 1991;12(6):429-437. Paolo Pronzalo; Paola Queirolo; Maria Giuseppina Vidili; Domenico Amoroso; Gianfdippo Berlelli; Mario
Roberto Sertoli; Riccardo Rosso
Continuous venous infusion of vinblastine in metastatic breast cancer
Chemotherapy. 1991;37(2):146-149. 1991
P. Pronzato; G. Bertelli; D. Amoroso; C. Pennucci; G. Gardin; T. Guido; P. Rosso
Oral chemotherapy with idarubicin plus cyclophosphamide in advanced breast cancer
Chemotherapy. 1991;37(6):449-453. 1991
1991
1990
1990
L. Miglietta; L. Repetto; G. Gardin; D. Amoroso; S. Guidici; C. Naso; L. Merlini; P. Queirolo; E. Campora;
P. Pronzato; R. Rosso
Tamoxifen and alpha interferon in advanced breast cancer
Journal of Chemotherapy. 1991;3(6):383-386. P. Pronzato; G. Bertelli; A. Mori; M. Rosalia Sarcona; G.P. Mortola
Computerized management of therapeutic protocols in oncology. Validation of a decisional
aid for breast cancer
Minerva Medica. 1991;82(11):733-736. P.F. Conte; G. Gardin; P. Pronzato; L. Miglietta; R. Rosso; D. Amadori; P. Gentilini; C. Monzeglio; P.
Gallotti; R. Demicheli; F. Brema; P. Sismondi; P. Miccoli; C. Lanfranco; F. Minuto; A. Barreca; P. Del
Monte
In vivo manipulation of human breast cancer growth by estrogens and growth hormone:
Kinetic and clinical results
Journal of Steroid Biochemistry and Molecular Biology. 1990;37(6):1103-1108. Paolo Pronzato; Fulvio Brema; Domenico Amoroso; Gianfilippo Bertelli; Pier Franco Conte; Maria Cristina
Martini; Gisella Pastorino; Riccardo Rosso
Megestrol acetate: Phase II study of a single daily administration in advanced breast cancer
Breast Cancer Research and Treatment. 1990;17(1):51-54. 1990
P. Pronzato; G. Bertelli; D. Amoroso; A. Gozza; A. Zaniboni; G. Marini; R. Rosso
Cisplatin and recombinant alpha interferon in advanced breast cancer
Annals of Oncology. 1990;1(2):150-151. 1990
1989
P. Pronzato; D. Amoroso; G. Bertelli; P. Queirolo; M.R. Sertoli; R. Rosso
Chemotherapy with mitomycin-C, epidoxorubicin and vinblastine in CMF failing breast
cancer patients
Anticancer Research. 1990;10(6):1743-1745. A. Ardizzoni; C. Pennucci; V. Fusco; M. Gulisano; M. Bonavia; P. Pronzato; M. De Palma; J. Serrano; R.
Rosso
1989
1989
1989
1989
1989
1988
1988
1988
Oral chemotherapy for poor risk small-cell lung cancer patients with combined idarubicin
and etoposide
Anticancer Research. 1989;9(4):937-940. G. Canavese; A. Catturich; G. Battistini; C. Caroti; P. Pronzato; G. Gardin; D. Amoroso; G. Bertelli; P.F.
Conte; S. Tomao; F. Badellino
The role of surgery in the combined treatment of locally advanced breast cancer
Oncology. 1989;46(6):353-356. R. Rosso; F. Boccardo; F. Brema; M.R. Sertoli; D. Amoroso; G. Bertelli; P. Pronzato
Adjuvant systemic treatment of resectable breast cancer: Eleven years results of a
monoinstitutional chemo-hormone-immunotherapy trial
Anticancer Research. 1989;9(4):1153-1156. D. Amoroso; G. Bertelli; P. Pronzato; M.G. Vidili; M. Gulisano; R. Lionetto; R. Rosso
Continuous venous infusion of vindesine in metastatic breast cancer: Experience with a
subcutaneously implanted system and portable pump
Anticancer Research. 1989;9(1):141-144. P. Pronzato; D. Amoroso; G. Bertilli; P.F. Conte; M.P. Cusimano; G.B. Ciottoli; M. Gulisano; R. Lionetto;
R. Rosso
Phase II study of lonidamine in metastatic breast cancer
British Journal of Cancer. 1989;59(2):251-253. P. Pronzato; E. Campora; D. Amoroso; G. Bertelli; F. Botto; P.F. Conte; M.R. Sertoli; R. Rosso
Impact of administration-related factors on outcome of adjuvant chemotherapy for primary
breast cancer
American Journal of Clinical Oncology: Cancer Clinical Trials. 1989;12(6):481-485. G. Bertelli; P. Pronzato; D. Amoroso; M.P. Cusimano; P.F. Conte; G. Montagna; S. Bertolini; R. Rosso
Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin
III levels
Breast Cancer Research and Treatment. 1988;12(3):307-310. Domenico Amoroso; Paolo Pronzato; Gianfilippo Bertelli; Pietro Gallotti; Gisella Pastorino; Maria Pia
Cusimano; Marco Merlano; Pier Franco Conte; Riccardo Rosso
Cisplatin and 5-fluorouracil in refractory breast cancer patients: A phase II study
Breast Cancer Research and Treatment. 1988;11(3):269-271. P. Pronzato; A. Ardizzoni; R. Lionetto; P.F. Conte; R. Rosso
Tamoxifen rechallenge.
Journal of clinical oncology : official journal of the American Society of Clinical
Oncology. 1988;6(4):751-752. 1988
F. Badellino; G. Canavese; A. Catturich; P.L. Percivale; C. Caroti; P. Pronzato; P.F. Conte
Chemotherapy and surgery related to breast cancer biology
Chirurgia. 1988;1(1):74-80. 1988
D. Amoroso; G. Bertelli; P. Pronzato; R. Rosso
Cisplatin plus 5-Fluorouracil in the treatment of advanced breast cancer
Folia Oncologica. 1988;11(2):173-175. 1988
Andrea Ardizzoni; Paolo Pronzato; Lazzaro Repetto; Mario De Palma; Luciano Canobbio; Marcella
Gulisano; Vittorio Fusco; Riccardo Rosso; Franco Ganzina
Phase II trial of oral idarubicin in advanced non-small cell lung cancer (NSCLC)
Cancer Investigation. 1988;6(4):409-411. 1988
G. Bertelli; D. Amoroso; P. Pronzato; R. Rosso
Idarubicin: An evaluation of cardiac toxicity in 77 patients with solid tumors
Anticancer Research. 1988;8(4):645-646. 1988
M.G. Vidili; G. Bertelli; D. Amoroso; P. Pronzato; R. Rosso
Continuous vindesine infusion in metastatic breast cancer
Folia Oncologica. 1988;11(2):176-178. 1988
G. Bertelli; D. Amoroso; P. Pronzato; R. Rosso
An evaluation of cardiac toxicity in 77 patients treated with idarubicin
Folia Oncologica. 1988;11(2):227-229. 1987
1987
A. Ardizzoni; V. Fusco; M. Gulisano; P. Pronzato; F. Baracco; A. Capaccio; G. Pastorino; M. Nosenzo; R.
Felletti; F. Fabiano
Etoposide, ifosfamide, and cisplatin in the treatment of advanced non-small cell lung
cancer.
Cancer Treatment Reports. 1987;71(12):1311-1312. P.F. Conte; A. Rubagotti; A. Falcone; G. Gardin; A. Nicolin; P. Pronzato; R. Rosso; D. Amadori; P.
Gentilini; P. Sismondi
Cytokinetic-based versus conventional chemotherapy in metastatic breast cancer: a
randomized study.
Chemioterapia. 1987;6(2 Suppl):712-713. 1987
R. Rosso; A. Ardizzoni; P. Conte; V. Fusco; M. Gulisano; R. Lionetto; P. Pronzato; L. Repetto
Phase II trials of idarubicin, a new anthracycline.
Chemioterapia. 1987;6(2 Suppl):694. 1987
1987
1987
P.F. Conte; P. Pronzato; A. Rubagotti; A. Alama; D. Amadori; R. Demicheli; G. Gardin; P. Gentilini; A.
Jacomuzzi; R. Lionetto
Conventional versus cytokinetic polychemotherapy with estrogenic recruitment in
metastatic breast cancer: Results of a randomized cooperative trial
Journal of Clinical Oncology. 1987;5(3):339-347. L. Repetto; P. Pronzato; A. Ardizzoni; G. Bertelli; M. Gulisano; D. Amoroso; G. Gardin; V. Fusco; A.
Falcone; P.F. Conte
Metastatic breast cancer: An analysis of prognostic factors in patients treated with
aminoglutethimide
Chemioterapia. 1987;6(1):66-72. R. Lionetto; P. Pronzato; P.F. Conte; D. Amoroso; F. Badellino; G. Bertelli; G. Canavese; G. Gardin; R.
Rosso
Multimodality treatment of locally advanced breast cancer
Oncology. 1987;44(3):137-141. 1987
P. Pronzato; D. Amoroso; A. Ardizzoni; G. Bertelli; P.F. Conte; A. Michelotti; R. Rosso
A phase II study with danazol in metastatic breast cancer
American Journal of Clinical Oncology: Cancer Clinical Trials. 1987;10(5):407-409. 1987
P. Pronzato; D. Amoroso; A. Ardizzoni; G. Bertelli; L. Canobbio; P.F. Conte; M.P. Cusimano; V. Fusco; M.
Gulisano; R. Lionetto; L. Repetto; R. Rosso
Sequential administration of cyclophosphamide, methotrexate, 5-fluorouracil, and folinic
acid as salvage treatment in metastatic breast cancer
American Journal of Clinical Oncology: Cancer Clinical Trials. 1987;10(5):404-406. 1986
Rita Lionetto; Paolo Pronzato; Gian Filippo Bertelli; Andrea Ardizzoni; Pier Franco Conte; Riccardo Rosso
Survival of patients with relapsing breast cancer: Analysis of 302 patients
Oncology (Switzerland). 1986;43(5):278-275. 1986
1986
1986
A. Ardizzoni; L. Canobbio; P. Pronzato; A. Rubagotti; M. De Palma; F. Baracco; J. Serrano; S. Serrano; B.
Faravelli; M. Nosenzo
Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell
carcinoma and adenocarcinoma of the lung
Cancer Treatment Reports. 1986;70(7):891-892. P. Pronzato; A. Ardizzoni; P.F. Conte; M. Gulisano; R. Lionetto; L. Repetto; V. Scornavacche; M.R.
Sertoli; R. Rosso
A phase II study of mitoxantrone in advanced breast cancer
Chemioterapia. 1986;5(3):150-153. A. Ardizzoni; L. Canobbio; P. Pronzato; L. Repetto; J. Serrano; F. Benvenuto; C. Simonassi; F. Baracco;
B. Faravelli; M. Nosenzo
Adriamycin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung
cancer
Chemioterapia. 1986;5(6):416-419. 1986
R. Lionetto; P. Pronzato; P.F. Conte; M.R. Sertoli; D. Amoroso; R. Rosso
Idarubicin in advanced breast cancer: A phase II study
Cancer Treatment Reports. 1986;70(12):1439-1440. 1985
A. Ardizzoni; P. Pronzato; L. Canobbio; R. Lionetto; R. Rosso
Failure of mitomycin-vindesine combination chemotherapy as salvage treatment for
metastatic breast cancer
Journal of Cancer Research and Clinical Oncology. 1985;110(1):77-78. 1985
M.T. Nobile; P. Pronzato; E. Campora; A. Ardizzoni; A. Grimaldi; R. Lionetto; L. Repetto; R. Rosso
Evaluation of 4-demethoxydaunorubicin toxicity (IMI 30). Preliminary data
Giornale italiano di chemioterapia. 1985;32(1):29-30. 1985
R. Lionetto; A. Ardizzoni; L. Repetto; P. Pronzato; M.R. Sertoli; R. Rosso
Phase II study of 4-demethoxydaunorubicin in metastatic breast neoplasms
Giornale italiano di chemioterapia. 1985;32(1):59-60. 1985
P. Pronzato; A. Ardizzoni; R. Lionetto; P. Conte; R. Rosso
Aminoglutethimide as second-line endocrine treatment in metastatic breast cancer
Tumori. 1985;71(3):297-300. 1985
A. Ardizzoni; R. Lionetto; L. Repetto; P. Pronzato; R. Rosso
Salvage chemotherapy with mitomycin C and vindesine in metastatic carcinoma of the
breast
Giornale italiano di chemioterapia. 1985;32(1):61-62. 1984
A. Ardizzoni; P. Pronzato; P.F. Conte; R. Rosso
Mitomycin C and 5-fluorouracil as second choice treatment in advanced breast cancer
patients
Chemioterapia. 1984;3(2):83-85. © 2016 Elsevier B.V All rights reserved. SciVal ® is a registered trademark of Elsevier Properties SA | About SciVal Experts | Terms and
conditions | Privacy statement | Contact